Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Cecilia R. Chambers

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4979-9349; OpenAlex author ID A5081385214. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer First author DOI 10.64898/2026.07.23.740234↗
  2. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  3. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  4. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  5. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  6. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  7. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  8. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. First author DOI 10.3390/cancers13143481↗
  9. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Co-author DOI 10.1016/j.trecan.2019.09.010↗
  10. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Herrmann · 3 shared papers, 2019–2021 · strength 0.35
  2. Brooke Pereira · 3 shared papers, 2019–2021 · strength 0.35
  3. Paul Timpson · 3 shared papers, 2019–2021 · strength 0.35
  4. Kendelle Joan Murphy · 2 shared papers, 2021 · strength 0.25
  5. Claire Vennin · 2 shared papers, 2019–2021 · strength 0.18
  6. Thomas R. Cox · 2 shared papers, 2019–2021 · strength 0.18
  7. Jennifer P. Morton · 2 shared papers, 2019–2021 · strength 0.18
  8. Yingxiao Wang · 1 shared paper, 2021 · strength 0.08
  9. Ashleigh Parkin · 1 shared paper, 2021 · strength 0.08
  10. Michael Tayao · 1 shared paper, 2021 · strength 0.08
  11. Jaswinder Singh Samra · 1 shared paper, 2021 · strength 0.08
  12. Angela S. Y. Chou · 1 shared paper, 2021 · strength 0.08
  13. Shona Ritchie · 1 shared paper, 2021 · strength 0.08
  14. Max Nobis · 1 shared paper, 2021 · strength 0.08
  15. Amber L. Johns · 1 shared paper, 2021 · strength 0.08
  16. Marina Pajic · 1 shared paper, 2021 · strength 0.08
  17. Roger J. Daly · 1 shared paper, 2021 · strength 0.08
  18. Sean Michael Grimmond · 1 shared paper, 2021 · strength 0.08
  19. Anthony James Gill · 1 shared paper, 2021 · strength 0.08
  20. James R. W. Conway · 1 shared paper, 2021 · strength 0.08
  21. Australian Pancreatic Cancer Genome Initiative (APGI) · 1 shared paper, 2021 · strength 0.08
  22. Owen James Sansom · 1 shared paper, 2021 · strength 0.08
  23. Andrew Victor Biankin · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.